The management of lung cancer has been transformed by the advent of molecularly targeted therapies, which have significantly improved outcomes for patients with specific genetic alterations, such as mutations in the anaplastic lymphoma kinase (ALK) gene [10] or the epidermal growth factor receptor (EGFR) gene [11]. Here, EGFR is linked to lung carcinoma.